Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
BLOOD-PLASMA PSEUDOURIDINE IN PATIENTS WITH MALIGNANT PROLIFERATIVE DISEASES
Autore:
MOTYL T; TRACZYK Z; CIESLUK S; DANIEWSKAMICHALSKA D; KUKULSKA W; KALUZNY Z; PODGURNIAK M; ORZECHOWSKI A; DEBSKI B;
Indirizzi:
AGR UNIV WARSAW,FAC VET MED,DEPT ANIM PHYSIOL,UL NOWOURSYNOWSKA 166 PL-02766 WARSAW POLAND CENT CLIN HOSP,DIV INTERNAL MED 4 WARSAW POLAND CENT HSOP,SCH MED,DEPT INTERNAL MED WARSAW POLAND AGR UNIV WARSAW,FAC VET MED,DEPT BIOCHEM PL-02528 WARSAW POLAND
Titolo Testata:
European journal of clinical chemistry and clinical biochemistry
fascicolo: 11, volume: 31, anno: 1993,
pagine: 765 - 771
SICI:
0939-4974(1993)31:11<765:BPIPWM>2.0.ZU;2-#
Fonte:
ISI
Lingua:
ENG
Soggetto:
MODIFIED NUCLEOSIDES; URINARY-EXCRETION; LIQUID-CHROMATOGRAPHY; ULTRAFILTRATED SERUM; RNA CATABOLITES; TUMOR-MARKER; LEUKEMIA; ACID; METABOLISM; CHILDHOOD;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
34
Recensione:
Indirizzi per estratti:
Citazione:
T. Motyl et al., "BLOOD-PLASMA PSEUDOURIDINE IN PATIENTS WITH MALIGNANT PROLIFERATIVE DISEASES", European journal of clinical chemistry and clinical biochemistry, 31(11), 1993, pp. 765-771

Abstract

The blood plasma concentration of pseudouridine was estimated in 104 healthy adult subjects, and 108 patients suffering from malignant proliferative diseases. The HPLC method for simultaneous determination of pseudouridine and creatinine was applied. The average physiological concentration of pseudouridine in blood plasma was 2.43 +/- 0.97 mumol .l-1 or 29.15 +/- 7.40 mmol . mol-1 creatinine. The physiological urinary excretion of pseudouridine was 14.32 +/- 5.20 mumol . 24 h-1 . kg-0.75 or 19.60 +/- 5.22 mmol . mol-1 creatinine. Renal clearance of pseudouridine and endogenous creatinine were 4.04 +/- 0.99 and 5.50 +/- 1.46 ml . kg-0.75 , respectively. A positive correlation (r = 0.55, P <0.01) was found between age (in the range 20-92 years) and blood plasma pseudouridine concentration (mumol . l-1). By expressing plasma pseudouridine in relation to plasma creatinine, the apparent influence ofnon-metabolic factors (age, renal insufficiency, blood dilution) on the plasma pseudouridine concentration were largely excluded. Among haematological proliferative diseases the highest values of plasma pseudouridine concentrations were observed in chronic lymphocytic leukaemia (8.19 mumol . l-1; 54.9 mmol . mol-1 creatinine) and multiple myeloma (7.02 mumol . l-1; 52.5 mmol . mol-1 creatinine). In multiple myeloma,but not in chronic lymphocytic leukaemia, the plasma pseudouridine concentration depended on the clinical stage. A lower, but still significant response in non-Hodgkin's lymphoma was noted (4.03 mumol . l-1; 40.88 mmol . mol-1 creatinine). A significant increase of the plasma pseudouridine concentration was characteristic of adenocarcinomas of thelarge intestine, and it occurred in the early stages of malignant growth. In patients with lung cancer the plasma pseudouridine concentration was elevated only in advanced cases with metastases. The increased pseudouridine concentration was evident in all examined cancers of theurogenital system: cancer of the urinary bladder, cancer of the kidney, cancer of the prostate, and cancer of the testis. It is concluded that the determination of pseudouridine in blood plasma, particularly in relation to creatinine, is a valuable biochemical marker of accelerated turnover rate of nucleic acids associated with neoplastic growth.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 07/07/20 alle ore 15:35:55